Kudos to client and innovative health tech company Tivic Health Systems, Inc., on closing its registered public offering, raising approximately $4 million. The offering involved Tivic’s sale of an aggregate of 4,710,000 shares of its common stock, Series A warrants to purchase up to 4,710,000 shares of common stock and Series B warrants to purchase up to 7,065,000 shares of common stock, at a combined public offering price of $0.85 per share and accompanying warrants. The Series A warrants have an exercise price of $0.85 per share, are exercisable immediately and will expire one year after the date of issuance, and the Series B warrants have an exercise price of $0.85 per share, are exercisable immediately and will expire five years after the date of issuance.

Procopio’s Capital Markets & Securities practice managed the transaction on behalf of Tivic Health with Senior Associate Caitlin Murphey and Associate Rachel Edwards.

Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Its patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Its first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors.

 Learn more in Tivic Health’s press release.